IDF awarded NIH grant for advancing knowledge in PIDD through continuance of USIDNET program

The Immune Deficiency Foundation (IDF) is pleased to announce that it has been awarded the grant "Resources to Assist Investigations in Primary Immunodeficiency Diseases" from the National Institutes of Health (NIH).  This grant will allow IDF to continue to advance the detection, understanding, diagnosis and treatment of primary immunodeficiency diseases (PIDD) through their program, the United States Immunodeficiency Network (USIDNET).  

USIDNET is a team of leading immunologists whose purpose is to advance knowledge in the field of PIDD.  USIDNET solicits, develops, evaluates and implements clinical research strategies to advance the detection, understanding, diagnosis and treatment of PIDD. There are three main components: the national patient registry, a cell repository, and educational programs to train new investigators. The patient consented registry is central to USIDNET's goals to collect, supply and examine longitudinal data about the diagnosis, prognosis and best treatment strategies in PIDD.

"We are pleased to receive this grant that will allow us to continue the important work of USIDNET," said IDF president and founder Marcia Boyle.  "IDF has been administering patient registries for primary immunodeficiencies supported by the NIH since 1992 and we are excited about the potential of the new patient-consented registries to dramatically improve the treatment of patients."

The Principal Investigator on the grant, Dr. Charlotte Cunningham-Rundles from Mt. Sinai Medical Center added, "We are enormously pleased with the progress of USIDNET and are delighted to be able to both continue and accelerate the work in primary immune deficiency over the next five years. We thank all of our collaborators, friends in industry and government, and especially the patients who continue to inspire us."